Oncolytics Biotech Inc. (TSE:ONC – Get Free Report)’s stock price reached a new 52-week low on Tuesday . The stock traded as low as C$0.86 and last traded at C$0.86, with a volume of 47955 shares changing hands. The stock had previously closed at C$0.89.
Oncolytics Biotech Stock Performance
The stock’s fifty day moving average price is C$1.08 and its 200-day moving average price is C$1.29. The company has a debt-to-equity ratio of 11.75, a quick ratio of 8.86 and a current ratio of 2.99. The company has a market capitalization of C$66.28 million, a P/E ratio of -2.40 and a beta of 1.35.
About Oncolytics Biotech
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
Further Reading
- Five stocks we like better than Oncolytics Biotech
- Stock Market Sectors: What Are They and How Many Are There?
- Arqit Stock Soars as NVIDIA’s GTC Fuels Quantum Excitement
- Stock Analyst Ratings and Canadian Analyst Ratings
- 3 Must-Own Stocks to Build Wealth This Decade
- Short Selling – The Pros and Cons
- Advanced Micro Devices Eyes AI Market Growth—Is AMD a Buy?
Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
